Fortress Biotech第三季总净收入1920万美元增约9%：现金1.522亿美元、净亏损790万美元
生物制药公司 Fortress Biotech 于 2026 年 11 月 13 日在迈阿密公布 2026 年第三季业绩与近期公司进展，业绩期截至 2026 年 9 月 30 日。
公司第三季合并净收入为 1920 万美元，上年同期为 1760 万美元，按公司业绩稿标题口径增约 9%。其中已上市皮肤科产品贡献 1890 万美元，上年同期为 1700 万美元，Journey Medical 报告的产品净收入同为 1890 万美元，上年同期为 1700 万美元。
第三季归属普通股股东的合并净亏损为 790 万美元、每股 0.23 美元，上年同期为净收益 370 万美元、每股基本 0.13 美元、摊薄 0.11 美元。
截至 2026 年 9 月 30 日，公司合并现金与现金等价物为 1.522 亿美元，较 2025 年 12 月 31 日的 7940 万美元增加。公司前九个月净收入为 5390 万美元，上年同期为 4720 万美元，其中产品净收入为 5270 万美元。
Fortress 是一家以收购与推进资产为模式的生物制药公司，收入来源包括产品收入、股权持有以及股息与特许权收入。Journey Medical 为其上市皮肤科产品的主要经营主体。
Fortress Biotech Third-Quarter Total Net Revenue Rises About 9 Percent to 19.2 Million Dollars: Cash of 152.2 Million Dollars and a Net Loss of 7.9 Million Dollars
Fortress Biotech, an innovative biopharmaceutical company, announced financial results and recent corporate highlights for the third quarter ended September 30, 2026 in Miami on November 13, 2026.
Fortress' consolidated net revenue totaled 19.2 million dollars for the third quarter of 2026, of which 18.9 million dollars was generated from marketed dermatology products. This compares with consolidated net revenue of 17.6 million dollars for the third quarter of 2025, of which 17.0 million dollars came from marketed dermatology products. Journey Medical reported net product revenues of 18.9 million dollars for the quarter, against 17.0 million dollars a year earlier.
Consolidated net loss attributable to common stockholders was 7.9 million dollars, or 0.23 dollars per share basic and diluted, for the third quarter of 2026, compared with net income attributable to common stockholders of 3.7 million dollars, or 0.13 dollars per share basic and 0.11 dollars diluted, a year earlier.
As of September 30, 2026, Fortress' consolidated cash and cash equivalents totaled 152.2 million dollars, compared with 79.4 million dollars as of December 31, 2025. Net revenue for the first nine months of 2026 was 53.9 million dollars, against 47.2 million dollars a year earlier, including product revenue, net of 52.7 million dollars.
Fortress focuses on acquiring and advancing assets to enhance long-term value for shareholders through product revenue, equity holdings and dividend and royalty income. Journey Medical is the main operating business behind its marketed dermatology products.
来源：Fortress Biotech
发布：GSM·美国（发布链接）
图片来源：图：神经元显微影像（Fortress Biotech相关资料图）。Madalena Simões-Abade，CC BY-SA 4.0，Wikimedia Commons。 / Photo: 神经元显微影像. Madalena Simões-Abade, CC BY-SA 4.0, via Wikimedia Commons.
GSM Global · 本篇英文版 English edition of this story
